Advertisement
Screener

Eton Pharmaceuticals, Inc. (ETON) Interest and Other Income

3.0 / 5 stars · 30/50 Roast Me

Eton Pharmaceuticals, Inc. Interest and Other Income

Eton Pharmaceuticals, Inc. (ETON) reported Interest and Other Income of $281.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.

Discontinued › Income Statement › Other Income

us-gaap:InterestAndOtherIncome · last filed 2020-03-05

  • Eton Pharmaceuticals, Inc. interest and other income for the quarter ending 2019-12-31 was -$40.00K, a 148.78% decline year-over-year.
  • Eton Pharmaceuticals, Inc. interest and other income for the quarter ending 2019-09-30 was $77.00K, a 208.00% increase year-over-year.
  • Eton Pharmaceuticals, Inc. interest and other income for the quarter ending 2019-06-30 was $100.00K, a 257.14% increase year-over-year.
  • Eton Pharmaceuticals, Inc. interest and other income for the quarter ending 2019-03-31 was $144.00K, a 396.55% increase year-over-year.
  • Eton Pharmaceuticals, Inc. interest and other income for fiscal 2019 was $281.00K, a 71.34% increase from fiscal 2018.
  • Eton Pharmaceuticals, Inc. interest and other income for fiscal 2018 was $164.00K.
Period endInterest and Other Income 3 monthInterest and Other Income 5 monthInterest and Other Income 6 monthInterest and Other Income 8 monthInterest and Other Income 9 monthInterest and Other Income 12 month
2019-12-31-$40.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05
$37.00K
derived: sum of 2 quarters · filed 2020-03-05
$137.00K
derived: sum of 3 quarters · filed 2020-03-05
$281.00K
10-K · filed 2020-03-05
2019-09-30$77.00K
10-Q · filed 2019-11-14
$177.00K
derived: sum of 2 quarters · filed 2019-11-14
$321.00K
10-Q · filed 2019-11-14
$403.00K
derived: sum of 4 quarters · filed 2020-03-05
2019-06-30$100.00K
10-Q · filed 2019-08-06
$244.00K
10-Q · filed 2019-08-06
$326.00K
derived: sum of 3 quarters · filed 2020-03-05
$351.00K
derived: sum of 4 quarters · filed 2020-03-05
2019-03-31$144.00K
10-Q · filed 2019-05-07
$226.00K
derived: sum of 2 quarters · filed 2020-03-05
$251.00K
derived: sum of 3 quarters · filed 2020-03-05
$279.00K
derived: sum of 4 quarters · filed 2020-03-05
2018-12-31$82.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05
$107.00K
derived: sum of 2 quarters · filed 2020-03-05
$135.00K
derived: sum of 3 quarters · filed 2020-03-05
$164.00K
10-K · filed 2020-03-05
2018-09-30$25.00K
10-Q · filed 2019-11-14
$53.00K
derived: sum of 2 quarters · filed 2019-11-14
$82.00K
10-Q · filed 2019-11-14
2018-06-30$28.00K
10-Q · filed 2019-08-06
$57.00K
10-Q · filed 2019-08-06
2018-03-31$29.00K
10-Q · filed 2019-05-07
2017-12-31$35.00K
10-K · filed 2020-03-05
2017-09-30$9.00K
10-Q · filed 2018-12-20
$9.00K
10-Q · filed 2018-12-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xencor Inc (XNCR)United States$1.776B-7.33
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Septerna, Inc. (SEPN)United States$1.783B-63.01
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
COMPASS Pathways plc (CMPS)$1.812B-4.87
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20